ArticleCell death and differentiation2013
Cell surface-expressed phosphatidylserine as therapeutic target to enhance phagocytosis of apoptotic cells.
Article in Cell death and differentiation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Potential Targets to Mitigate Trauma- or Sepsis-Induced Immune Suppression.Frontiers in immunology · 2021Pooled it
- Stem cells redirect the neuroinflammatory trajectory of primed microglia in an ovine chorioamnionitis model.Brain, behavior, & immunity - health · 2026Article
- Macrophage efferocytosis promotes inflammation resolution and accelerates wound healing.Communications biology · 2026Review
- Efferocytosis: The Silent Guardian of Tissue Homeostasis and Cardiovascular Health.Journal of cardiovascular development and disease · 2025Review
- Enhancing antiretroviral delivery to secondary lymph nodes by targeting CD169 + macrophages with HIV-mimicking nanoparticles.Scientific reports · 2025Article
- Tailored brain metastatic tumor cells-derived apoptotic bodies ameliorate Alzheimer's disease by promoting microglia efferocytosis and neuroinflammation mitigation.Journal of nanobiotechnology · 2025Article
- Immunomodulatory effect of efferocytosis at the maternal-fetal interface.Cell communication and signaling : CCS · 2025Review
- Emerging nanoprobes for the features visualization of vulnerable atherosclerotic plaques.Smart medicine · 2024Review
- A novel opsonic eCIRP inhibitor for lethal sepsis.Journal of leukocyte biology · 2024Article
- Vascular lipidomics analysis reveales increased levels of phosphocholine and lysophosphocholine in atherosclerotic mice.Nutrition & metabolism · 2023Article
- BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity.Experimental & molecular medicine · 2022Article
- Extracellular Vesicles and Thrombosis: Update on the Clinical and Experimental Evidence.International journal of molecular sciences · 2021Review
- Senescence under appraisal: hopes and challenges revisited.Cellular and molecular life sciences : CMLS · 2021Review
- Mechanisms for Reducing Neuropathic Pain.Molecular neurobiology · 2020Review
- CaJournal of clinical medicine · 2019Review
- AnnexinA5-pHrodo: a new molecular probe for measuring efferocytosis.Scientific reports · 2018Article
- Phosphatidylserine-mediated platelet clearance by endothelium decreases platelet aggregates and procoagulant activity in sepsis.Scientific reports · 2017Article
- Efferocytosis Signaling in the Regulation of Macrophage Inflammatory Responses.Journal of immunology (Baltimore, Md. : 1950) · 2017Review
- Pharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR-/- Mice on Western Type Diet.PloS one · 2015Article
- AnxA5 reduces plaque inflammation of advanced atherosclerotic lesions in apoE(-/-) mice.Journal of cellular and molecular medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impaired efferocytosis has been shown to be associated with, and even to contribute to progression of, chronic inflammatory diseases such as atherosclerosis. Enhancing efferocytosis has been proposed as strategy to treat diseases involving inflammation. Here we present the strategy to increase 'eat me' signals on the surface of apoptotic cells by targeting cell surface-expressed phosphatidylserine (PS) with a variant of annexin A5 (Arg-Gly-Asp-annexin A5, RGD-anxA5) that has gained the function to interact with α(v)β(3) receptors of the phagocyte. We describe design and characterization of RGD-anxA5 and show that introduction of RGD transforms anxA5 from an inhibitor into a stimulator of efferocytosis. RGD-anxA5 enhances engulfment of apoptotic cells by phorbol-12-myristate-13-acetate-stimulated THP-1 (human acute monocytic leukemia cell line) cells in vitro and resident peritoneal mouse macrophages in vivo. In addition, RGD-anxA5 augments secretion of interleukin-10 during efferocytosis in vivo, thereby possibly adding to an anti-inflammatory environment. We conclude that targeting cell surface-expressed PS is an attractive strategy for treatment of inflammatory diseases and that the rationally designed RGD-anxA5 is a promising therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.